Actinium Pharmaceuticals Inc (STU:7AY1)
€ 1.321 -0.001 (-0.08%) Market Cap: 41.72 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 1.15 GF Score: 27/100

Actinium Pharmaceuticals Inc at B Riley Securities Oncology Conference (Virtual) Transcript

Jan 19, 2023 / 03:30PM GMT
Release Date Price: €9.67 (+0.78%)
Yuan Zhi
B. Riley Securities, Inc. - Analyst

All right. Good morning, everyone. Welcome to B. Riley Securities oncology conference on day two and listening to our fireside chat. I'm Yuan Zhi, a healthcare equity research analyst at B. Riley Securities. It is my great pleasure to have Sandesh Seth, CEO of Actinium Pharmaceuticals.

Thank you for joining us today, and congrats on a very productive 2022 and congrats on ringing the closing bell at NYSE today. Now we have some great news from this ARROW trial not a long ago, and it is exciting to see the full data will be presented as a late breaker at a tandem meeting on February 18 in Florida.

In addition to that, we also have an oral presentation at ASH conference from the Actimab program. Before we talk about this in detailed progress, Sandesh, maybe you can give the audience a quick overview of your clinical programs and the platform.

Sandesh Seth
Actinium Pharmaceuticals, Inc. - CEO

Yeah, sure. So thanks for having me, appreciate it. looking forward to the data on February 18. So company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot